---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-086710"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T08:15:33.571685+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine reports FY2022 net loss $46.8M; cash $194.6M; bitopertin Phase 2 trials ongoing

## Summary
- Net loss of $46.8M for FY2022 vs $36.0M in 2021; R&D expenses $33.4M, G&A $14.0M.
- Cash and equivalents $194.6M as of Dec 31, 2022, up from $88.0M; expects to fund operations into 2025.
- Bitopertin Phase 2 BEACON (EPP/XLP) interim data expected 1H 2023; AURORA topline data by end 2023.
- DISC-0974 Phase 1b/2 in MF and NDD-CKD initiated; interim data expected end 2023.
- Annual meeting June 9, 2023; record date April 14; stockholder proposal deadline April 10.

## SEC filing metadata
- accession: 0001193125-23-086710
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.08, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312523086710/0001193125-23-086710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312523086710/d463005d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-086710
- JSON: https://secwatch.observer/filing/0001193125-23-086710.json
- Plain text: https://secwatch.observer/filing/0001193125-23-086710.txt

## Key facts
- Earnings Releases
  Disc Medicine, Inc. reported financial results for the full year ended December 31, 2022.
  - Period: the full year ended December 31, 2022
  - Result: reported results
  source text: On March 31, 2023, Disc Medicine, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2022 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312523086710/0001193125-23-086710-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.